Array
(
[1576494752] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1576494765] => Array
(
[wpseo_ping_search_engines] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1576496373] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1576496881] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1576498352] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576501650] => Array
(
[publish_future_post] => Array
(
[f044e7d06ad064b739799cff5cdd31a2] => Array
(
[schedule] =>
[args] => Array
(
[0] => 480659
)
)
)
)
[1576503126] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1576503874] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576504199] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[ccee4635eaa1c5c68847742cf6f56334] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1576504199
)
)
)
)
[1576508400] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1576509473] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1576512424] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576515411] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576566512] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576572571] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576577711] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576577752] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576763399] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[9b181c9e6b126f6f93b7b0404ada1528] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1576763399
)
)
)
)
[1580169600] => Array
(
[publish_future_post] => Array
(
[2d492587fa52e9c78f7043ddf937b0a1] => Array
(
[schedule] =>
[args] => Array
(
[0] => 18611
)
)
[dea3edad73162f380bc9dc44fa3407bf] => Array
(
[schedule] =>
[args] => Array
(
[0] => 19670
)
)
[2caa9c58a241c4f77a6856802c1b43fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 20734
)
)
[307b37ba29b8cd716eafa809661756e3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 22852
)
)
[365be9eba8e62abb0c0d4bfe013a2687] => Array
(
[schedule] =>
[args] => Array
(
[0] => 23918
)
)
[0e942b20ffb9550322105263ad82126f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 24977
)
)
[661c5eb39689fe2133ff7986ac6628fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 26036
)
)
[75562b264e355915e4dea97042a28f7e] => Array
(
[schedule] =>
[args] => Array
(
[0] => 27095
)
)
[11cf4e8a6f842b0115881551a29c47f6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 28154
)
)
[55a38aaca11da398c854cb29a7d4f5e6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 30272
)
)
[f8cbc904676c235c7057ec965c01c023] => Array
(
[schedule] =>
[args] => Array
(
[0] => 32390
)
)
)
)
[1583794819] => Array
(
[publish_future_post] => Array
(
[9d993985746691420cd7524448c48a23] => Array
(
[schedule] =>
[args] => Array
(
[0] => 448880
)
)
)
)
[1601157627] => Array
(
[publish_future_post] => Array
(
[aa3f9c41dd8e97586795881a0c603b8d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 472787
)
)
)
)
)
Etiquetas: AEMPS, Agencia española de medicamentos y productos sanitarios, Alertas, Cambios de especial interés sanitario en medicamentos ya autorizados, Cosméticos, Información de interés, Información sobre seguridad, Madrid, marzo 2008, medicamentos, Medicamentos de uso humano y productos sanitarios, Médico, Mensual, Nota, Nota mensual, Nuevos medicamentos, Otra información de interés, Paciente, Productos de higiene personal, Productos sanitarios, Radiofármacos, salud, Sanidad.
Etiquetas: Abilify, Abril 2008, Aceite de crisálida, Acetato de icatibanto, Ácido nicotínico, AEMPS, AESAN, Agencia española de medicamentos y productos sanitarios, Agencia Española de Seguridad Alimentaria y Nutrición, Alertas de productos sanitarios, Aminas aromáticas, Antagonista de los receptores de Angiotensina II, Apidra, ARAII, Aripiprazol, Atazanavir, Azopt, Brinzolamida, Bromuro de metilnaltrexona, Cambios de especial interés sanitario en medicamentos ya autorizados, CHMP, Cinacalcet, Comité de Evaluación de Medicamentos de la Agencia Europea, Cosméticos, Crikes, D.A.D, Data Collection of Adverse effects of anti-HIV Drugs, Dictamen positivo, Efficib, Enzima convertidora de Angiotensina, Evaluación de la Asociación de Abacabir y Didanosinacon incremento del riesgo de infarto de miocaardio, Firazyr, Hidrocloruro de metformina, IECA, Información sobre seguridad, Insulina glulisina, Intenze Colors, Janumet, Laropiprant, Latixa, Lista, Madrid, Medicamentos de uso humano y productos sanitarios, Millenium, Mimpara, Ministrio de Sanidad Y Consumo, Monohidrato de sitagliptina fosfato, Neupro, Nota mensual, Notas informativas, Nuevos medicamentos aprobados, Parareg, Pelzont, posibles alteraciones hepáticas asociadas al consumo de roductos Herbalife, Principio activo, principios activos, Productos de higiene personal, Profesionales sanitarios, Pseudomonas Aeruginosa, Ranolazina, Red de Alerta Alimentaria, Relistor, Reyataz, Riesgos de uso durante el embarazo, Rotigotina, salud, Sanidad, SEFV, Sistema Coordinado de Intercambio Rápido de Información, Sistema Español de Farmacovigilancia, Tintas de tatuaje no autorizadas, Tintes azoicos, Tredaptive, Trevaclyn, Velmetia, Whitefarm Diekés Dietbe.
Etiquetas: AEMPS, Agencia española de medicamentos y productos sanitarios, Alertas, AZARGA, Cambios de especial interés sanitario en medicamentos ya autorizados, CANCIDAS, Caspofungina, CLEXANE, Cosméticos, Dictamen positivo para su autorización, Dihidrocloruro de sapropterina, Enoxaparina sódica, Información de interés, Información sobre seguridad, KUVAN, Leucoencefalopatía Multifocal Progresiva, LMP, Madrid, medicamentos, Medicamentos de uso humano y productos sanitarios, Médico, Mensual, Natalizumab, Nota, Nuevos medicamentos, Otra información de interés, Paciente, Pamoato de olanzapina, Productos de higiene personal, Productos sanitarios, Radiofármacos, salud, Sanidad, septiembre 2008, Tecnecio, Tratamiento, TYSABRI, ZIPHADERA.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)